Skip to content

Disc Medicine IRON Net Investment in Lease

Net Investment in Lease at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
Beam Therapeutics logo
Beam TherapeuticsBEAM
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's net investment in lease?
Disc Medicine (IRON) reported net investment in lease of $967K in Q1 2026.
How has Disc Medicine's net investment in lease changed year-over-year?
Disc Medicine's net investment in lease decreased by 33.6% year-over-year, from $1.46M to $967K.
What is the long-term trend for Disc Medicine's net investment in lease?
Over 4 years (2021 to 2025), Disc Medicine's net investment in lease has grown at a 53.0% compound annual growth rate (CAGR), from $200K to $1.1M.